Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679362 | 0.72 | CXCR4 (0.44) | CYP1A2 | |
| SCHEMBL17288868 | 0.72 | CXCR4 (0.44) | CYP1A2 | |
| SCHEMBL7006302 | 0.72 | CHRNB2 (0.57) | — | |
| SCHEMBL24984263 | 0.66 | CXCR4 (0.54) | — | |
| SCHEMBL7010738 | 0.65 | GABRA1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL29232360 | 0.65 | CXCR4 (0.53) | — | |
| Hydrochloric Acid SCHEMBL30918505 | 0.65 | CXCR4 (0.53) | — | |
| Hydrochloric Acid SCHEMBL29232308 | 0.64 | CXCR4 (0.62) | — | |
| SCHEMBL25087416 | 0.64 | HRH3 (0.41) | CYP1A2BRD4CTDSP1 | |
| SCHEMBL18664073 | 0.64 | ACHE (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | claimed |
| EP-1280793-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2003-02-05 | — | — | EP | claimed |
| WO-2001081334-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | claimed |
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1280793-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001081334-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | CHRM1, CHRM5, CCKAR | CYP1A2 2232/4885GRIN2B 314/4885GRIN1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.